Table 1 Clinicopathological characteristics of breast cancer patients with different BMI included in the screening cohort
Clinical variables | Screening cohort (n) | |
|---|---|---|
NW (9) (BMI < 24.9 kg/m2) | OW/Ob (18) (BMI ≥ 25 kg/m2) | |
Age, y | ||
 Median | 44 | 55 |
 Range | 30–73 | 36–76 |
 BMI Kg/m2, mean ± SD | 21.7 ± 2.5 | 30.6 ± 4.06 |
Histology, % | ||
 In situ ductal carcinoma | 0 | 5.5 |
 Invasive ductal carcinoma | 100 | 83.3 |
 Invasive lobular carcinoma | 0 | 11.2 |
Grading, % | ||
 Well differentiated (G1) | 0 | 11.1 |
 Moderately differentiated (G2) | 33.3 | 55.6 |
 Poor/undifferentiated (G3) | 44.4 | 22.2 |
 Unknown | 22.2 | 11.1 |
Menopausal status, % | ||
 Premenopausal | 88.8 | 50 |
 Postmenopausal | 11.2 | 50 |
Estrogen receptor status, % | ||
 Negative | 22.2 | 5.5 |
 Positive (> 1%) | 77.7 | 94.4 |
Progesterone receptor status, % | ||
 Negative | 22.2 | 22.2 |
 Positive (> 1%) | 77.7 | 77.7 |
HER2/Neu status, % | ||
 Negative | 77.7 | 72.2 |
 Positive | 22.2 | 27.7 |
Ki67, % | ||
  < 14 | 0 | 11.2 |
  ≥ 14 | 100 | 88.8 |